Eli Lilly and Company (LLY)
Eli Lilly Stock Dives Toward Worst Day Since 2000 On Disappointing Earnings, Zepbound Sales
Drug maker Eli Lilly's share price plunged Wednesday morning after the company reported worse third-quarter results than expected, especially in its weight-loss drug division, registering a rare misstep for the Wall Street darling.
Eli Lilly tumbles as weight loss drug sales underwhelm, guidance slashed
Eli Lilly and Co (NYSE:LLY) shares fell over 12% on Wednesday after the drug maker slashed guidance for the year following underwhelming figures for the third quarter. Sales of Eli's blockbuster weight loss drug Zepbound fell short of analysts' expectations, at $1.26 billion compared to estimates for $1.76 billion.
Eli Lilly (LLY) Lags Q3 Earnings and Revenue Estimates
Eli Lilly (LLY) came out with quarterly earnings of $1.18 per share, missing the Zacks Consensus Estimate of $1.52 per share. This compares to earnings of $0.10 per share a year ago.
Eli Lilly's stock tumbles as Mounjaro, Zepbound sales miss by wide margins
Eli Lilly's stock heads for biggest selloff since 2008 after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.
Eli Lilly Stock Tumbles as Q3 Sales, Profits Fall Well Short of Estimates
Eli Lilly (LLY) shares tumbled 10% after its third-quarter results fell well short of analysts' estimates before the bell Wednesday.
Eli Lilly Dives On Earnings Miss As Diabetes, Weight-Loss Drugs Fall Short
Eli Lilly earnings and revenue missed Q3 views, with sales light for its diabetes and weight-loss drugs. Eli Lilly stock dived Wednesday.
Eli Lilly stock tumbles 10% after missing estimates and slashing profit guidance
Eli Lilly reported third-quarter adjusted profit and revenue that missed expectations, sending its stock tumbling roughly 10% Skyrocketing demand for injectable weight loss and diabetes drugs has forced both Eli Lilly and its main rival, Novo Nordisk, to invest billions to increase manufacturing capacity.
Eli Lilly misses third-quarter profit amid soaring demand for weight-loss drug
Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, even as demand for its weight-loss drug soared, hurt by higher manufacturing and acquisition-related costs.
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years
Eli Lilly has a number of lucrative opportunities that should serve as tailwinds for sustained growth.
Can Mounjaro, Zepbound Help Eli Lilly Top Earnings Estimates Again?
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines, Mounjaro and Zepbound.
Gradual dosing of Lilly Alzheimer's drug cuts brain-swelling risk, study finds
Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients experiencing potentially serious brain swelling, according to interim results of a late-stage trial presented at a medical meeting on Tuesday.
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains
Eli Lilly and Co LLY will be reporting its third-quarter earnings on Wednesday. Wall Street expects $1.45 in EPS and $12.10 billion in revenues as the company reports at 10 a.m.
